KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $544.1 million.

  • Resmed's Cost of Revenue rose 249.99% to $544.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 billion, marking a year-over-year increase of 303.06%. This contributed to the annual value of $2.1 billion for FY2025, which is 302.28% up from last year.
  • According to the latest figures from Q4 2025, Resmed's Cost of Revenue is $544.1 million, which was up 249.99% from $514.8 million recorded in Q3 2025.
  • Resmed's Cost of Revenue's 5-year high stood at $544.1 million during Q4 2025, with a 5-year trough of $321.5 million in Q1 2021.
  • In the last 5 years, Resmed's Cost of Revenue had a median value of $503.2 million in 2023 and averaged $465.4 million.
  • In the last 5 years, Resmed's Cost of Revenue surged by 53.66% in 2021 and then surged by 3371.07% in 2023.
  • Quarter analysis of 5 years shows Resmed's Cost of Revenue stood at $390.6 million in 2021, then increased by 16.25% to $454.0 million in 2022, then increased by 13.62% to $515.9 million in 2023, then grew by 2.9% to $530.8 million in 2024, then increased by 2.5% to $544.1 million in 2025.
  • Its Cost of Revenue stands at $544.1 million for Q4 2025, versus $514.8 million for Q3 2025 and $527.9 million for Q2 2025.